Nevirapina Teva Italia (Nevirapine)

Nevirapine, the active ingredient in Nevirapina Teva Italia, is a Non‑nucleoside reverse transcriptase inhibitor (NNRTI) presented as an oral tablet for oral use. It is indicated for the treatment of HIV‑1 infection, typically as part of combination antiretroviral therapy in adults and adolescents.

GNH USA supplies Nevirapina Teva Italia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nevirapine is used in the management of HIV‑1 infection and related therapeutic regimens.

HIV‑1 infection: reduces viral replication and helps achieve undetectable viral load. Treatment‑naïve patients: forms part of first‑line combination antiretroviral therapy. Prevention of mother‑to‑child transmission: used with other agents to lower transmission risk during pregnancy and delivery.

Nevirapine may cause a range of adverse reactions, from mild to severe, which should be monitored during therapy.

Common Side Effects: - Rash: mild to moderate skin eruptions. - Headache: transient, often resolves with continued use. - Nausea: occasional gastrointestinal discomfort. - Fatigue: feeling of tiredness or weakness. - Diarrhea: loose stools, usually mild.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention. - Hepatotoxicity: elevated liver enzymes or hepatitis. - Severe rash or hypersensitivity: may progress to systemic involvement. - Anemia: reduction in red blood cell count. - Immune reconstitution syndrome: worsening of opportunistic infections after immune recovery.

Patients should be evaluated for potential risks before initiating nevirapine therapy.

Baseline liver function tests: assess hepatic health prior to treatment. HIV‑1 viral load monitoring: ensure therapeutic effectiveness. Pregnancy considerations: discuss risks and benefits with a healthcare provider. Concomitant medications: review for possible interactions. Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Nevirapine can affect the plasma concentrations of several co‑administered drugs.

Major Interactions (Avoid): - Rifampicin: reduces nevirapine levels, compromising efficacy. - Certain protease inhibitors (e.g., ritonavir): may increase toxicity risk. - St. John’s wort: induces metabolism, lowering drug exposure.

Moderate Interactions (Monitor Closely): - Warfarin: may alter anticoagulant effect, requiring INR monitoring. - Oral contraceptives: reduced effectiveness, consider alternative contraception. - Efavirenz: combined use may increase hepatic toxicity risk.